912,921 Shares in Aytu BioPharma Inc. $AYTU Acquired by Stonepine Capital Management LLC

Stonepine Capital Management LLC purchased a new position in Aytu BioPharma Inc. (NASDAQ:AYTU) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 912,921 shares of the company’s stock, valued at approximately $1,962,780,000. Aytu BioPharma makes up approximately 1.1% of Stonepine Capital Management LLC’s portfolio, making the stock its 28th largest position. Stonepine Capital Management LLC owned 0.09% of Aytu BioPharma as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in AYTU. BlackRock Inc. acquired a new position in shares of Aytu BioPharma during the second quarter worth approximately $49,000. Rothschild Wealth LLC acquired a new stake in Aytu BioPharma in the 4th quarter valued at $52,000. Dimensional Fund Advisors LP bought a new stake in Aytu BioPharma during the 3rd quarter valued at $58,000. XTX Topco Ltd bought a new stake in Aytu BioPharma during the 4th quarter valued at $67,000. Finally, DRW Securities LLC acquired a new position in Aytu BioPharma during the fourth quarter worth $76,000. Institutional investors and hedge funds own 33.49% of the company’s stock.

Aytu BioPharma Stock Down 2.6%

Shares of NASDAQ:AYTU opened at $2.24 on Friday. The business’s 50 day moving average is $2.24 and its 200 day moving average is $2.36. Aytu BioPharma Inc. has a 12-month low of $1.65 and a 12-month high of $3.07. The stock has a market cap of $24.04 million, a price-to-earnings ratio of -0.49 and a beta of 0.25. The company has a quick ratio of 1.00, a current ratio of 1.12 and a debt-to-equity ratio of 0.27.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the stock. Zacks Research raised shares of Aytu BioPharma from a “strong sell” rating to a “hold” rating in a research note on Thursday, August 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Aytu BioPharma in a research report on Monday, July 6th. Finally, Ascendiant Capital Markets upped their target price on shares of Aytu BioPharma from $14.00 to $14.50 and gave the stock a “buy” rating in a report on Thursday, June 11th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Aytu BioPharma currently has an average rating of “Hold” and an average target price of $10.75.

Aytu BioPharma Company Profile

Aytu BioPharma, Inc is a specialty pharmaceutical company focused on the development, licensing and commercialization of novel therapeutics to address underserved medical needs. Headquartered in Englewood, Colorado, Aytu pursues a strategy of acquiring late-stage or approved products in areas such as urology, endocrinology, women’s health, pediatric care and supportive therapies. The company leverages in-house commercialization capabilities and targeted business development to build a diversified portfolio of prescription medicines and diagnostics.

Aytu’s marketed portfolio includes Natesto, a nasal testosterone gel for treatment of male hypogonadism; ZolpiMist, a zolpidem tartrate lingual spray for the short-term treatment of insomnia; and Tuzistra XR, an extended-release cough syrup formulation indicated for relief of cough and upper respiratory symptoms.